Holen Sie sich die Stockscreener-App
23.70
0.42%
-0.02
Schlusskurs vom Vortag:
$23.72
Offen:
$23.51
24-Stunden-Volumen:
101.95K
Relative Volume:
0.20
Marktkapitalisierung:
$1.65B
Einnahmen:
$133.62M
Nettoeinkommen (Verlust:
$-177.37M
KGV:
-11.07
EPS:
-2.14
Netto-Cashflow:
$23.50M
1W Leistung:
+0.52%
1M Leistung:
+12.06%
6M Leistung:
-0.62%
1J Leistung:
+27.68%
1-Tages-Spanne:
$23.50
$23.86
1-Wochen-Bereich:
$22.60
$23.86
52-Wochen-Spanne:
$15.31
$26.84
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Vergleichen Sie XNCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| XNCR | 23.72 | 1.65B | 133.62M | -177.37M | 23.50M | -2.14 |
| VRTX | 447.17 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.51 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.70 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.25 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor Reports Q3 2024 Earnings and Program Updates - TipRanks
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross - MSN
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
(XNCR) Proactive Strategies - Stock Traders Daily
EcoR1 Capital, LLC Increases Stake in Xencor Inc - GuruFocus.com
US Bancorp DE Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor CEO Dahiyat Bassil sells shares worth $80,841 - Investing.com
Xencor executive sells shares worth $1.6 million By Investing.com - Investing.com Australia
Xencor executive sells shares worth $1.6 million - Investing.com India
PRIMECAP Management Bolsters Stake in Xencor Inc - GuruFocus.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead - Investing.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com UK
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% - Yahoo Finance UK
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Creative Planning - Defense World
Xencor’s (XNCR) “Outperform” Rating Reiterated at BMO Capital Markets - Defense World
Xencor (NASDAQ:XNCR) Given New $28.00 Price Target at JPMorgan Chase & Co. - Defense World
Xencor (NASDAQ:XNCR) Given Outperform Rating at Wedbush - Defense World
What is Wedbush’s Forecast for Xencor FY2024 Earnings? - Defense World
Leerink Partnrs Increases Earnings Estimates for Xencor - Defense World
Leerink Partnrs Brokers Lift Earnings Estimates for Xencor - MarketBeat
What is Wedbush's Forecast for Xencor FY2024 Earnings? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Xencor (NASDAQ:XNCR) Receives "Outperform" Rating from BMO Capital Markets - MarketBeat
Xencor shares target raised, rating held on pipeline progress By Investing.com - Investing.com Canada
Xencor shares target raised, rating held on pipeline progress - Investing.com
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Xencor (NASDAQ:XNCR) shareholders are up 7.9% this past week, but still in the red over the last three years - Simply Wall St
Xencor Reports Third Quarter 2024 Financial Results - BioSpace
Xencor Inc earnings beat by $0.27, revenue fell short of estimates - Investing.com Canada
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor: Q3 Earnings Snapshot - San Antonio Express-News
Trading (XNCR) With Integrated Risk Controls - Stock Traders Daily
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - BioSpace
Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com
942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? - Yahoo Finance
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts - Defense World
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):